We report net peptide content, not just purity — so the milligrams you dose aren't padded with water and counter-ion. RP-HPLC purity and ESI-MS identity, on a lot-numbered COA.
Net peptide content, not just purity — RP-HPLC + ESI-MS, lot-numbered COA.
Net peptide content on every lot's COA.
Reading a Peptide HPLC Trace — A 5-Minute Field Guide for Bench Scientists. Read our briefing →
Reading a peptide HPLC trace — a field guide. Read →
On reading HPLC traces. Read →
GHRH analog · approved for HIV-associated lipodystrophy
Lyochem buyer fit
This Lyochem page is intentionally written for research labs, core facilities, and method-development teams qualifying Tesamorelin as a reference-grade lot. It is not the pharmacy procurement owner for this SKU; the page should win differentiated searches around sequence verification, assay suitability, lot continuity, and data-packet depth.
Overview
Tesamorelin is a 44-residue GHRH analog bearing an N-terminal trans-3-hexenoyl cap that shields it from DPP-4 proteolysis and prolongs plasma exposure relative to native GHRH or unmodified Sermorelin. Distinct within its class, it is the sole FDA-approved GHRH analog, marketed as the finished drug Egrifta for reducing excess visceral abdominal fat in HIV-associated lipodystrophy. Lyochem supplies Tesamorelin acetate as a lyophilized reference standard at ≥99.0% HPLC. At 44 residues the sequence occupies the upper-middle band of SPPS difficulty, and identity hinges on the acylation: ESI-MS confirming the N-terminal hexenoyl-modified mass is the diagnostic release check, run alongside peak-integration HPLC. Because the hexenoyl group's positional integrity governs activity, LC-MS/MS sequence verification is offered on request and advised when qualifying a new supplier. The material is typically ordered either as a standalone vial for visceral-fat and compounding research or as the pre-blended Tesamorelin + Ipamorelin product (the tesa-ipa-blend SKU) for dual-pathway GH-axis studies.
Applications & buyer fit
GH-axis peptides ship to research labs studying somatotropic-pathway pharmacology, IGF-axis signalling, and pulse vs. sustained-elevation GH biology. Buyers qualifying a new source typically request sequence verification on the first lot, the counter-ion form (acetate by default), and stability data at −20 °C. Blends — the CJC-1295 + Ipamorelin co-formulated lot is the canonical example — are co-lyophilised rather than solution-mixed so the ratio is locked at the lyophilisation step.
Biotech R&D Groups
Preclinical biotech and pharmaceutical discovery teams sourcing characterized peptides for receptor-pharmacology, screening, and method-development campaigns.
Academic Laboratories
Universities, medical schools, and government research institutes qualifying a reference standard for a method-development or in vivo workflow.
Every release ships with its own batch-specific CoA — identity, purity, and the analytical scope agreed at quote stage, tied to the exact lot you receive.
Review a representative batch CoA before you order, so you can confirm the packet matches what your method or sponsor audit needs.
Supplied strictly as a research reagent to research institutions — not a finished dosage form and not for human administration. Buyer qualification runs at the inquiry stage.
Specifications
Documentation available on request
Regulatory note
The finished Tesamorelin drug (Egrifta) is FDA-approved for HIV-associated lipodystrophy. Lyochem supplies the bulk active strictly for Research Use Only; buyers are responsible for verifying ingredient eligibility in their destination market.
Selected literature
Frequently asked questions
The N-terminal acyl modification shifts the intact mass well above the unmodified 1-29 backbone, so ESI-MS reading roughly 5135.8 Da against about 3358 Da for Sermorelin 1-29 is the primary identity signal, and confirming that the higher-mass species is the dominant peak rules out substantial unmodified contaminant. Mass alone, however, does not localize the acyl group to the correct terminus, so LC-MS/MS coverage of the N-terminal residues is added to show the hexenoyl sits where the structure requires rather than on an internal side chain.
The chromatogram should show at least 99.0% main-peak area, but the packet extends past that single figure. It pairs the HPLC purity with ESI-MS confirming the modified mass, LC-MS/MS localizing the hexenoyl to the N-terminus, and the water content plus counter-ion identity that convert weighed mass into net peptide. For workflows moving material into in vivo research, LAL endotoxin and USP microbial-limits testing are added, since those readouts are sensitive to contamination the identity and purity assays do not detect.
Related peptides
29-mer
GHRH 1-29 fragment
Modified GRF 1-29 · GHRH analog
Co-characterized GH-axis pairing (Tesamorelin + Ipamorelin)